Figure 3.

Canagliflozin activates the ⍺1AMPK/p38MAPK/HSP27 pathway in HMECs. HMECs were treated with canagliflozin (Cana) for the indicated concentrations during one hour. Cell lysates were submitted to western blot analysis and probed with total and phosphorylated (a) ⍺1AMPK (Thr172), (b) ACC (Ser79), (c) p38 MAPK (Thr180/Tyr182) and (d) HSP27(Ser82) antibodies, (e) Molecular mechanisms underlying the protective action of canagliflozin on interendothelial junctions. Representative western blots and quantification are shown. Data are fold of the 3 µM condition and expressed as mean ± SEM (3 to 6 biological replicates for each condition). *p < 0.05 is relative to untreated HMECs. The data underwent one-way ANOVA.